SDH-Deficient Gastrointestinal Stromal Tumor (GIST) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Gastrointestinal stromal tumors (GISTs) are the predominant mesenchymal tumors in the gastrointestinal tract. They primarily occur in the stomach (50%-60%) and small intestine (30%-35%), while their occurrence in the colon and rectum is less common (5%), and in the esophagus, it is rare (<1%). Additionally, GISTs can develop within the abdominal cavity, specifically in the omentum, mesentery, or retroperitoneum (occurring in less than 5% of all GISTs). Specific mutations in the KIT gene drive the majority of GISTs (75%-80%) or PDGFRA gene (10%). However, around 10%-15% of GISTs do not exhibit detectable mutations in KIT or PDGFRA and are called KIT/PDGFRA wild-type GISTs. Succinate dehydrogenase comprises four subunit proteins (SDHA, SDHB, SDHC, and SDHD) and two assembly factors (SDHAF1 and SDHAF2). SDHA and SDHB form the catalytic component of succinate-coenzyme Q reductase, whereas SDHC and SDHD comprise the anchoring component that attaches the complex to the inner mitochondrial membrane. These tumors are more commonly observed in children and young adults. Most gastric GIST patients under 18 years old and a significant percentage of patients under 30 years old fall into this category. While the exact cause of SDH deficiency in these tumors remains unclear, the association between SDH deficiency and SDH gene mutations is well-established. The primary function of SDH is to participate in the interface between the tricarboxylic acid cycle and the electron transport chain. It catalyzes the oxidation of succinate to fumarate. This complex plays a crucial role in regulating hypoxia-inducible factor 1α (HIF1α), which is a subunit of HIF1. HIF1 is a transcriptional activator of IGF2 and VEGF. SDH-deficient GISTs present clinical manifestations similar to other gastric tumors, including gastrointestinal bleeding and epigastric discomfort. Some patients diagnosed with SDH-deficient GISTs may exhibit symptoms associated with metastatic tumors in the abdomen or liver. The differential diagnosis for SDH-deficient GISTs is comparable to that of other gastrointestinal stromal tumors, which include carcinoma, perivascular epithelioid cell tumor, melanoma, epithelioid leiomyosarcoma, epithelioid angiosarcoma, glomus tumor, and even neuroendocrine tumors, especially when the tumor demonstrates epithelioid morphology. Traditional chemotherapy has limited efficacy in treating GISTs; however, the tyrosine kinase inhibitor imatinib has shown promising results in inhibiting their growth.

  • The overall incidence of GISTs was 0.70 per 100,000 people per year. Approximately 5% to 7.5% of all GISTs are SDH-deficient.

Thelansis’s “SDH-Deficient Gastrointestinal Stromal Tumor (GIST) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential SDH-Deficient Gastrointestinal Stromal Tumor (GIST) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of SDH-Deficient Gastrointestinal Stromal Tumor (GIST) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

SDH-Deficient Gastrointestinal Stromal Tumor (GIST) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: SDH-Deficient Gastrointestinal Stromal Tumor (GIST) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more